http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market
-
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
-
Scopus BioPharma to Present at the LD Micro Main Event
-
Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference
-
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
-
Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference
-
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Scopus BioPharma Inc. (SCPS) Announces China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
-
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
-
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board
-
Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
-
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
-
Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
-
Scopus BioPharma Launches Duet Therapeutics
-
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
-
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
-
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
-
Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders
-
Scopus BioPharma (SCPS) Announces FDA Approval of IND Application for Lead Drug Candidate
-
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
-
Scopus BioPharma (SCPS) Announces IND Submission to FDA for Lead Drug Candidate
-
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate
-
Scopus BioPharma Inc. (SCPS) Finalizes Arrangements for Submission of IND Package
-
Scopus BioPharma Finalizes Arrangements for Submission of IND Package
-
Scopus BioPharma Announces Completion of Clinical Lot Manufacture
-
Scopus BioPharma Announces Appointment of Additional Directors

